faropenem sodium hydrate Search Results


faropenem sodium hydrate  (Millipore)
90
Millipore faropenem sodium hydrate
Faropenem Sodium Hydrate, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/faropenem sodium hydrate/product/Millipore
Average 90 stars, based on 1 article reviews
faropenem sodium hydrate - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
faropenem sodium hydrate powder  (BOC Sciences)
90
BOC Sciences faropenem sodium hydrate powder
Exposure-effect relationship of <t>faropenem</t> and Mycobacterium tuberculosis ( Mtb ) on day 7 using inhibitory sigmoid maximal kill (E max ) model. Treatment with static concentrations of faropenem for 7 days resulted in a E max of 2.71 log 10 colony-forming units (CFU)/mL with an exposure mediating 50% of E max of 11.09 mg/L ( r 2 = 0.91), as shown in the equation, which is a kill rate similar to, and better than, most currently used antituberculosis agents.
Faropenem Sodium Hydrate Powder, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/faropenem sodium hydrate powder/product/BOC Sciences
Average 90 stars, based on 1 article reviews
faropenem sodium hydrate powder - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
faropenem sodium hydrate  (Aladdin Scientific Corporation)
N/A
Faropenem is a broad-spectrum penem antibiotic. It is active against a panel of 12 Gram-positive (MIC50s = 0.008-1 mg/L) and 15 Gram-negative (MIC50s = 0.06-16 mg/L) bacteria. Faropenem (20 mg/kg) reduces the number of lung
   Buy from Supplier
faropenem sodium hydrate  (Biosynth Carbosynth)
N/A
   Buy from Supplier

Image Search Results


Exposure-effect relationship of faropenem and Mycobacterium tuberculosis ( Mtb ) on day 7 using inhibitory sigmoid maximal kill (E max ) model. Treatment with static concentrations of faropenem for 7 days resulted in a E max of 2.71 log 10 colony-forming units (CFU)/mL with an exposure mediating 50% of E max of 11.09 mg/L ( r 2 = 0.91), as shown in the equation, which is a kill rate similar to, and better than, most currently used antituberculosis agents.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

doi: 10.1093/cid/ciw474

Figure Lengend Snippet: Exposure-effect relationship of faropenem and Mycobacterium tuberculosis ( Mtb ) on day 7 using inhibitory sigmoid maximal kill (E max ) model. Treatment with static concentrations of faropenem for 7 days resulted in a E max of 2.71 log 10 colony-forming units (CFU)/mL with an exposure mediating 50% of E max of 11.09 mg/L ( r 2 = 0.91), as shown in the equation, which is a kill rate similar to, and better than, most currently used antituberculosis agents.

Article Snippet: Faropenem sodium hydrate powder was purchased from BOC Sciences (Shirley, New York).

Techniques:

Faropenem exposure-response in combination regimen. A , Effect of different faropenem % of time concentration persists above minimum inhibitory concentration (%T MIC ) and linezolid-moxifloxacin regimen on THP-1 cells. There was no effect of faropenem exposures on THP-1 cells. B , Effect of different faropenem exposures in combination with the linezolid-moxifloxacin regimen based on an exponential decline model for Mycobacterium tuberculosis ( Mtb ) log 10 colony-forming units (CFU)/mL. The faropenem T MIC of 62.5% had a steeper slope than 12.5% and 25%. There was no convergence for the exponential decline model for nontreated controls, as expected, given they did not decline.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

doi: 10.1093/cid/ciw474

Figure Lengend Snippet: Faropenem exposure-response in combination regimen. A , Effect of different faropenem % of time concentration persists above minimum inhibitory concentration (%T MIC ) and linezolid-moxifloxacin regimen on THP-1 cells. There was no effect of faropenem exposures on THP-1 cells. B , Effect of different faropenem exposures in combination with the linezolid-moxifloxacin regimen based on an exponential decline model for Mycobacterium tuberculosis ( Mtb ) log 10 colony-forming units (CFU)/mL. The faropenem T MIC of 62.5% had a steeper slope than 12.5% and 25%. There was no convergence for the exponential decline model for nontreated controls, as expected, given they did not decline.

Article Snippet: Faropenem sodium hydrate powder was purchased from BOC Sciences (Shirley, New York).

Techniques: Concentration Assay

Microbial responses to optimized faropenem-based regimens in a paucibacillary model. A , The experimental faropenem, linezolid, and moxifloxacin (FLM) regimen and high-dose moxifloxacin (FLM Hi ) plus ethambutol (EMB), as well as the standard therapy regimen, had killed Mycobacterium tuberculosis ( Mtb ) in the pediatric hollow fiber system model for intracellular tuberculosis systems below colony-forming unit (CFU)/mL assay limits, suggesting complete sterilization. B , The time to positivity (TTP) assay revealed that there was still bacterial growth with the FLM regimen and standard regimen; the former has statistically higher TTP compared with standard regimen at the end of experiment, suggesting better kill rates.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

doi: 10.1093/cid/ciw474

Figure Lengend Snippet: Microbial responses to optimized faropenem-based regimens in a paucibacillary model. A , The experimental faropenem, linezolid, and moxifloxacin (FLM) regimen and high-dose moxifloxacin (FLM Hi ) plus ethambutol (EMB), as well as the standard therapy regimen, had killed Mycobacterium tuberculosis ( Mtb ) in the pediatric hollow fiber system model for intracellular tuberculosis systems below colony-forming unit (CFU)/mL assay limits, suggesting complete sterilization. B , The time to positivity (TTP) assay revealed that there was still bacterial growth with the FLM regimen and standard regimen; the former has statistically higher TTP compared with standard regimen at the end of experiment, suggesting better kill rates.

Article Snippet: Faropenem sodium hydrate powder was purchased from BOC Sciences (Shirley, New York).

Techniques:

Effect of a new faropenem, linezolid, and moxifloxacin (FLM) regimen over 1 month. A , Kill slopes of the different regimens based on a linear regression model and 95% confidence bounds. The r 2 for the FLM regimen was 0.92, for high-dose moxifloxacin (FLM Hi ) was 0.84, for FLM Hi with ethambutol (EMB) was 0.84, and for standard therapy was 0.73. B , Exponential decline model. The decline rates of all the regimens were similar to standard therapy. C , Time to positivity (TTP) of contents from each hollow fiber system shows that there is no sterilization up to day 28 with TTP when compared to Mycobacterium tuberculosis ( Mtb ) log colony-forming units (CFU)/mL, which revealed sterilization. In this experiment we started with a higher bacterial burden, an acid test. Results of multiple t test comparison shown as * P value of .045 on day 7 and ** P = .011 for day 21. However, by day 28 the TTPs were similar in all drug treatment regimens.

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

doi: 10.1093/cid/ciw474

Figure Lengend Snippet: Effect of a new faropenem, linezolid, and moxifloxacin (FLM) regimen over 1 month. A , Kill slopes of the different regimens based on a linear regression model and 95% confidence bounds. The r 2 for the FLM regimen was 0.92, for high-dose moxifloxacin (FLM Hi ) was 0.84, for FLM Hi with ethambutol (EMB) was 0.84, and for standard therapy was 0.73. B , Exponential decline model. The decline rates of all the regimens were similar to standard therapy. C , Time to positivity (TTP) of contents from each hollow fiber system shows that there is no sterilization up to day 28 with TTP when compared to Mycobacterium tuberculosis ( Mtb ) log colony-forming units (CFU)/mL, which revealed sterilization. In this experiment we started with a higher bacterial burden, an acid test. Results of multiple t test comparison shown as * P value of .045 on day 7 and ** P = .011 for day 21. However, by day 28 the TTPs were similar in all drug treatment regimens.

Article Snippet: Faropenem sodium hydrate powder was purchased from BOC Sciences (Shirley, New York).

Techniques: Comparison